SCYNEXIS Q4 EPS $(1.05) Misses $(0.77) Estimate

SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.77) by 36.36 percent. This is a 72.22 percent increase over losses of $(3.78) per share from the

byBenzinga Newsdesk

March 29, 2022

1 minute read

SOBR Safe Announces Pricing Of $6 Million Private Placement Priced At-the-Market

By Michael Horton

September 28, 5:18 PM

SOBR Safe, Inc. (NASDAQ:SOBR) (the "Company" or "SOBRsafe"), providers of industry-leading alcohol screening solutions, today announced that it entered into a securities purchase agreement with

SOBR

Piper Sandler Maintains Overweight on Autodesk, Lowers Price Target to $298

By Benzinga Newsdesk

February 25, 5:44 AM

Piper Sandler analyst Weston Twigg maintains Autodesk (NASDAQ:ADSK) with a Overweight and lowers the price target from $340 to $298.

ADSK

Lexaria Bioscience Reports First Phase Of Its Epilepsy Research Program Begun This Week; DehydraTECH-CBD Test Articles Have Been Manufactured, Delivered To Third-Party Lab Engaged To Complete Research

By Benzinga Newsdesk

March 15, 2:12 PM

Program EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECHTM-CBD for reducing seizure activity; DehydraTECH-CBD test articles have been delivered to the laboratory ready to commence dosing.

LEXX